Keklikoglou, Ioanna http://orcid.org/0000-0003-1219-6912
Cianciaruso, Chiara
Güç, Esra
Squadrito, Mario Leonardo http://orcid.org/0000-0002-1188-0299
Spring, Laura M.
Tazzyman, Simon
Lambein, Lore
Poissonnier, Amanda
Ferraro, Gino B.
Baer, Caroline
Cassará, Antonino
Guichard, Alan
Iruela-Arispe, M. Luisa http://orcid.org/0000-0002-3050-4168
Lewis, Claire E.
Coussens, Lisa M.
Bardia, Aditya
Jain, Rakesh K.
Pollard, Jeffrey W. http://orcid.org/0000-0003-4579-0053
De Palma, Michele http://orcid.org/0000-0001-9128-5459
Article History
Received: 4 September 2016
Accepted: 20 November 2018
First Online: 31 December 2018
Competing interests
: L.M.S. reports consulting fees from Novartis. L.M.C. is a paid consultant for Cell Signaling Technologies, received reagent support from Plexxikon and NanoString Technologies and is a member of the Scientific Advisory Boards of Syndax Pharmaceuticals, Carisma Therapeutics and Verseau Therapeutics. A.B. reports consulting fees from Genentech/Roche, Immunomedics, Novartis, Pfizer, Merck, Radius Health, Spectrum Pharma and Taiho Pharma and received a research grant from Biothernostics. R.K.J. received honoraria from Amgen and consultancy fees from Merck, Ophthotech, Pfizer, SPARC, SynDevRx, and XTuit, owns equity in Enlight, Ophthotech, SynDevRx and serves on the Boards of Trustees of Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund and Tekla World Healthcare Fund. M.D.P. reports honoraria from Merck and Sanofi/Regeneron Pharmaceuticals, received sponsored research grants from Hoffmann La-Roche, MedImmune and Deciphera Pharmaceuticals and serves on the Scientific Advisory Boards of Deciphera Pharmaceuticals and Genenta. The other authors declare no competing interests. Neither materials nor funding from the above organizations were used in this study.